REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus BioSciences Inc. (CHRS) on Monday reported a loss of $56.6 million in its first quarter. The Redwood City, California-based ...

Shareholders appeared to be happy with Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) solid earnings report last week. Looking deeper at the numbers, we found several encouraging factors ...

Coherus BioSciences Inc. (CHRS) reported its Q1 2025 earnings results, revealing a flat revenue of $7.3 million, despite a 15% growth in patient demand. According to InvestingPro data, the company ...

FRAMINGHAM, Mass. (AP) — FRAMINGHAM, Mass. (AP) — Xenetic Biosciences, Inc. (XBIO) on Tuesday reported a loss of $903,000 in its first quarter. The Framingham, Massachusetts-based company said ...

"Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology," said Dr. Yuling Luo, CEO, Founder and Chairman of Alamar Biosciences. "By integrating assays for ...

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Precision BioSciences Inc. (DTIL) on Thursday reported a loss of $20.6 million in its first quarter. On a per-share basis, the Durham, North Carolina ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

SelectR Biosciences reported a significant improvement in its financial performance for Q1 2025, with a net loss reduction to $6.6 million, or $0.14 per share, compared to a $26.6 million loss ...

A partnership between Zeiss and Alpenglow Biosciences has been created to develop new light-sheet microscopy (LSM) implementations for clinical applications. The goal is to leverage enhanced imaging ...

Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel ...

Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 14, 2025 ...

--(BUSINESS WIRE)--EnPlusOne Biosciences, Inc., a biotechnology company pioneering enzymatic solutions for RNA manufacturing, will present new data from its proprietary ezRNA™ platform at TIDES ...